Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Baby formula company stops production again due to storms

It is unclear when the facility will restart production

Graig Graziosi
Thursday 16 June 2022 19:28 BST
Comments
Related video: Mother confronts woman over hoarding baby formula amid shortage crisis
Leer en Español

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Abbott Nutrition, a Michigan baby formula factory whose temporary shuttering contributed to the formula shortage, has once again closed, this time due to inclement weather.

MLive reports that the factory suspended production on its EleCare specialty formulas, but noted that there is enough supply to meet current demand.

The company ramped up production of the formula for infants with severe food allergies and digestive problems prior to the second shut down.

The factory was damaged and needs re-sanitizing following severe thunderstorms and heavy rains that moved through Michigan on Monday. The company did not specify the extent of the damage to the facility.

“Severe thunderstorms and heavy rains came through southwestern Michigan on Monday evening, resulting in high winds, hail, power outages and flood damage throughout the area,” Abbott said in a statement Wednesday night. “These torrential storms produced significant rainfall in a short period of time – overwhelming the city’s stormwater system in Sturgis, Mich., and resulting in flooding in parts of the city, including areas of our plant."

US Food and Drug Administration Commissioner Dr Robert Califf said in a tweet that the agency would be working alongside Abbott to get the facility back up and producing as soon as possible.

“We know Abbott is working quickly to assess the damage and will be reporting its progress to us in the days ahead. Once the company establishes a plan, FDA will be back in the facility working to ensure that they can restart producing safe and quality formula products quickly,” he wrote.

Abbott restarted production at the factory on 4 June after contamination issues forced it to close back in February, which ultimately was a major factor in the formula shortage plaguing the nation.

In February, the Food and Drug Administration launched an investigation into four bacterial infections that affected infants who consumed the factory's powdered formulas. Two of those babies died, which resulted in the closure.

The company has insisted that its products were not directly related to the infections.

FDA inspectors ultimately found numerous violations at the plant, including bacterial contamination, leaks in the roof, and insufficient safety protocols.

Following the inquiry, Abbot recalled several of its leading brands, including Similac.

The company has not said when its facility would re-open.

“As a result, Abbott has stopped production of its EleCare specialty formula that was underway to assess damage caused by the storm and clean and re-sanitize the plant," the company said. "We have informed FDA and will conduct comprehensive testing in conjunction with the independent third party to ensure the plant is safe to resume production. This will likely delay production and distribution of new product for a few weeks.”

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in